Industry News
Pharmaceutical Industry News
Some four months after the White…
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. government is back for round 2, this time lining up
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
BioMarin now collects royalties on…
BioMarin now collects royalties on the more convenient competitor product. Ascendis will pay 20% of Yuviwel net sales in the U.S. dating back to the first commercial sales and through to May 2030.
Samanta Cimitan, Ph.D., will serve…
Samanta Cimitan, Ph.D., will serve in a newly created role as the CDMO's chief commercial officer, SVP and member of the extended executive committee starting Jan. 1, 2027.
The FDA sent Alar Pharmaceuticals…
The FDA sent Alar Pharmaceuticals an untitled letter after finding fault with the company’s exhibit booth display and brochure at a recent conference.
Jazz Pharmaceuticals has added a…
Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new HER2 agent of choice in stomach cancer.
Late August has been rough for IV…
Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame.
After a surprise washout in a…
After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis’ antisense oligonucleotide Wainua, the likely reason for the miss is being laid bare, in a potential ill omen for others pursuing
Walmart to Pay $50 Million to Settle Opioid Lawsuit, US Says
The resolution is part of an effort to hold retailers and pharmacists accountable for what the government says were their roles in the opioid epidemic.
The FDA has approved Takeda’s…
The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm.
The FDA has signed off on a label…
The FDA has signed off on a label expansion for PharmaEssentia's Besremi, endorsing it as a treatment for the rare bone marrow disorder essential thrombocythemia.
In their high-profile competition…
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with Novo Nordisk. On Friday, Lilly checked another item off that list as it secured FDA
Biogen highlighted patient…
Biogen highlighted patient advocate and content creator Naomi Rose’s story living with cutaneous lupus erythematosus (CLE) on its social media platforms.
Omnicom’s maslansky + partners…
Omnicom’s maslansky + partners has expanded its leadership team, hiring two new partners and expanding the role of a founding partner to strengthen its healthcare and life science practice.
Stephen Farquhar has taken over as…
Stephen Farquhar has taken over as CEO of Publicis Health Media (PHM), succeeding longtime Publicis executive Andrea Palmer.
Though not without a bump along…
Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease.
Roche is taking a less-trodden…
Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over shrinking lung cancer data for ivonescimab. A U.S. congressman says China is "beating us on our ground game" in biotech. Plus more.
Cytokinetics’ cardiac myosin…
Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningful benefits in patients with a rare heart condition called non-obstructive hypertrophic cardiomyopathy. An approval for this indication could potentially double the pool
Bristol Myers Squibb will spend…
Bristol Myers Squibb will spend $173 million to build a second radiopharmaceutical manufacturing facility in Indiana to couple with its current site in Indianapolis. The new plant will be in nearby Whitestown.
Ajaz Khan, M.D., a medical…
Ajaz Khan, M.D., a medical oncologist at City of Hope Chicago, was in the packed audience at this summer’s American Society of Clinical Oncology meeting when Revolution Medicines received a standing ovation for its groundbreaking